BioSpace News Archive

Disc Medicine, Inc. (NASDAQ:IRON) today reported financial results for the first quarter ending March 31, 2023 and provided an update on recent program and corporate developments.

uniQure N.V. announced it has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX® to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million in cash.

Minerva Neurosciences, Inc. reported business updates and financial results for the first quarter ended March 31, 2023.

Benitec Biopharma Inc., a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference platform, announced financial results for its Third Fiscal Quarter ended March 31, 2023.

Protara Therapeutics, Inc. (Nasdaq: TARA) today announced that patient dosing is now underway in its Phase 1b ADVANCED-1EXP expansion trial evaluating TARA-002, the Company’s investigational cell-based therapy, for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have carcinoma in situ (CIS).

Cue Biopharma, Inc. (Nasdaq: CUE) announced today the presentation of a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL.

STRATA Skin Sciences, Inc. announced it has entered into an exclusive, three-year agreement with Spectra Medical India Pvt Ltd., a distribution company representing medical laser and aesthetic equipment manufacturers, for the distribution of TheraClear®X, VTRAC®, and XTRAC® in India.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2023, its recent business highlights, and a preview of select anticipated milestones.

InspireMD, Inc. announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors that have agreed to provide up to $113.6 million in gross proceeds to InspireMD through a private placement that includes initial upfront funding of $42.2 million.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today reported financial results for the first quarter ended March 31, 2023 and corporate updates.